S7 Ep50: FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC
Nov 24, 2022
18:32
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr Abou-Alfa discusses the FDA approval of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma, the regimen’s unique mechanism of action, and the importance of expanding global access to this combination.
